Sd Biosensor

SD Biosensor is a leading Korean in-vitro diagnostics (IVD) company with a portfolio spanning immunochemistry diagnostics, self blood glucose monitoring, molecular diagnostics, and rapid antigen testing.

In the first half of 2026, its major product categories including immunochemistry diagnostics, blood glucose monitoring, and molecular diagnostics all showed solid momentum. Expanded sales of its point-of-care molecular diagnostics platform, the STANDARD M10, underpinned revenue growth.

Products certified under the World Health Organization's Prequalification (PQ) program are supplied to public health programs in low-income countries; in Africa, its combined HIV/syphilis rapid test achieved a 60% market share.

The company has also used a new plant in India to strengthen cost competitiveness for WHO PQ-certified products. In 2023, it acquired the Nasdaq-listed Meridian Bioscience to accelerate entry into the North American market, an area where the company had previously lacked meaningful sales.

Meridian's life-science raw materials and diagnostics business has little overlap with SD Biosensor's COVID-era product lines, and the United States is estimated to represent about 40% of the global IVD market as the single largest national market, making Meridian's distribution network and regulatory personnel a bridgehead for US entry.

Competition comes from a mix of global diagnostics majors and domestic and international IVD peers, and since the shift to a COVID-19 endemic phase, sustained growth in non-COVID products has become the central variable for earnings.

Earnings have swung sharply as the COVID-19 windfall faded and the Meridian acquisition weighed on results.

Revenue peaked at KRW 2,932.0 billion in 2022 with operating profit of KRW 1,146.6 billion and net profit of KRW 908.8 billion, but in 2023 revenue collapsed to KRW 655.7 billion with an operating loss of KRW 248.1 billion and a net loss of KRW 467.9 billion.

In 2024, revenue recovered modestly to KRW 694.6 billion, though the operating loss persisted at KRW 54.1 billion while the net loss narrowed to KRW 98.1 billion.

In 2025, revenue rose 2.3% year-on-year to KRW 710.6 billion, continuing its growth trend, but the operating loss widened to KRW 80.9 billion and the net loss reached KRW 513.4 billion (KRW 512.1 billion attributable to owners).

This large net loss was driven almost entirely by a single quarter—2025Q4 alone recorded a net loss attributable to owners of KRW 758.9 billion—which the company attributed to non-cash accounting charges from intangible amortization and goodwill/intangible impairment tied to the consolidation of Meridian Bioscience.

The trend has since improved markedly: net profit attributable to owners turned positive for two consecutive quarters, at KRW 22.7 billion in 2026Q1 and KRW 16.5 billion in 2026Q2, while the operating loss narrowed to KRW 11.6 billion and KRW 7.3 billion respectively, down sharply from KRW 20.6 billion in 2025Q2.

Over the trailing four quarters (2025Q3-2026Q2), cumulative revenue was KRW 738.8 billion against a net loss attributable to owners of KRW 729.5 billion, a figure still dominated by the 2025Q4 impairment charge.

The global IVD industry has undergone structural realignment as it shifts from the pandemic-era boom into an endemic phase.

With COVID-related revenue largely gone, companies are transitioning their business models toward steady-state, non-COVID demand in immunochemistry, molecular diagnostics, and blood glucose monitoring.

In markets serving low-income countries, WHO PQ certification and inclusion in national testing algorithms act as key entry barriers, an area where SD Biosensor holds an advantage in specific products such as its Africa HIV/syphilis test.

The United States is reportedly the single largest IVD market, accounting for roughly 40% of the global total, but high barriers to FDA approval for non-US medical device makers have made M&A, such as the Meridian acquisition, a common strategy for indirect market entry.

The competitive landscape features global diagnostics majors such as Roche and Abbott alongside numerous domestic and international IVD specialists, with many COVID-test-kit companies that saw revenue plunge after the pandemic now competing to expand non-COVID portfolios.

Against this backdrop, SD Biosensor is positioned with a diversified product portfolio combined with geographic expansion through overseas distributor acquisitions.

The company aims to sustain revenue growth through expanded sales of the M10 molecular diagnostics platform and balanced growth across its domestic and overseas subsidiaries, offsetting the loss of COVID-era revenue with its non-COVID product lines.

Management has outlined a mid- to long-term growth strategy centered on new diagnostic technology development, product line expansion, and strengthening its integrated diagnostics platform.

On shareholder returns, the company announced a plan to pay out at least 20% of standalone operating profit as cash dividends over the next three years, a structure in which actual dividend capacity will hinge on the pace of earnings recovery after several years of losses.

Regarding Meridian, the investor agreement with financial partner SJL Partners includes a "qualified listing" requirement for parent entity Columbus Holding Company to relist on Nasdaq or elsewhere by November 2028; failure to meet this condition allows SJL to exercise a buy-back right on its exchangeable bonds and equity stake.

This put option becomes exercisable in stages starting November 2026, the three-year mark from issuance, and since Meridian has posted net losses in every year since the acquisition, whether it can meet the listing requirement—and whether SJL chooses to exercise the option—stands out as a key variable over the coming months.

The parent company has already extended funds to help Meridian service its debt, so the impact of ongoing subsidiary liquidity support on the parent's own financial structure also warrants continued attention.